Some in CRISPR-Cas9-land who are focused on potential future clinical applications are kind of rejoicing or at least sighing a breath of relief. This upbeat swing in the atmosphere (from investors especially) was sparked by retraction of that paper, the one initially reporting tons of supposed off-target CRISPR-Cas9 activity in mice, which turned out to be a “nothing burger” according to one investment site. Off-target activity definitely still needs to be on people’s radar screens, but it’s a problem that’s not nearly so widespread as that paper incorrectly …Read More
Trusted stem cell blog & resources
